Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaQualia PharmaTSE:4579 -0.78%53 Graham Number is 円108.32 as of Mar. 2026, which is 100% below its 10-year median of 2.71. GuruFocus rates TSE:4579 with a GF Score™ of 53/100 and a GF Value™ of 円906.77 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 258 Biotechnology companies, RaQualia Pharma ranks worse than 82.17% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-08-17), the stock price of RaQualia Pharma is 円512.00. RaQualia Pharma's graham number for the quarter that ended in Mar. 2026 was 円108.32. Therefore, RaQualia Pharma's Price to Graham Number ratio for today is 4.73.
The historical rank and industry rank for RaQualia Pharma's Graham Number or its related term are showing as below:
TSE:4579'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.39 Med: 2.71 Max: 7.18
Current: 4.73
During the past 13 years, the highest Price to Graham Number ratio of RaQualia Pharma was 7.18. The lowest was 1.39. And the median was 2.71.
TSE:4579's Price-to-Graham-Number is ranked worse than 82.17% of 258
companies
in the Biotechnology industry
Industry Median: 1.855
vs TSE:4579: 4.73
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
RaQualia Pharma (TSE:4579) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
RaQualia Pharma's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
512.00
/
108.32
=
4.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
RaQualia Pharma Graham Number Related Terms
RaQualia Pharma Graham Number Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, RVMD: Graham Number Comparison
For the Biotechnology subindustry, RaQualia Pharma's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a Graham Number of 円108.32 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on RaQualia Pharma and its competitors. This is 3897% above median its historical median of 2.71. Over the past decade, RaQualia Pharma's Graham Number has ranged from 1.39 to 7.18. According to the industry distribution chart, RaQualia Pharma ranks #212 out of 258 companies in the Biotechnology industry, placing it in the top 82.2%.
Is RaQualia Pharma's Graham Number too high?
RaQualia Pharma's current Graham Number of 円108.32 is 3897% above median its 10-year median of 2.71. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 7.18. Based on the distribution chart, RaQualia Pharma ranks #212 out of 258 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RaQualia Pharma has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Graham Number compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #212 out of 258 companies for Graham Number. This places RaQualia Pharma in the lower half of its industry. The industry median Graham Number is 1.86. Historically, RaQualia Pharma's own Graham Number has ranged from 1.39 to 7.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.86, based on 258 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median Graham Number is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current Graham Number is 円108.32, which is 3897% above median its own 10-year median of 2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円906.77, compared to a current price of 円512.00 — trading 43.5% below its estimated fair value. The current Graham Number is 円108.32, which is 3897% above median its 10-year median of 2.71. RaQualia Pharma's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Graham Number is 円108.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円512.00 is trading 43.5% below its estimated GF Value™ of 円906.77.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
Graham Number: 円108.32 (3897% above median its 10-year median of 2.71)
GF Value™: 円906.77 vs. price of 円512.00 (43.5% below fair value)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
53GF Score
Get the complete analysis for TSE:4579
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
